Sionna Therapeutics, Inc./$SION
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Sionna Therapeutics, Inc.
Sionna Therapeutics Inc is a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) patients by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein to deliver clinically meaningful benefit to CF patients. CF is a progressive and life-threatening genetic disease caused by inherited mutations in the CFTR gene, which heads to insufficient CFTR function. The Company is managed as one operating segment focused on the research and development of cystic fibrosis therapies.
Ticker
$SION
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
48
ISIN
US8294011080
Website
SION Metrics
BasicAdvanced
$698M
-
-$6.81
-
-
Price and volume
Market cap
$698M
52-week high
$18.85
52-week low
$7.26
Average daily volume
201K
Financial strength
Current ratio
28.727
Quick ratio
28.305
Long term debt to equity
2.382
Total debt to equity
2.7
Profitability
EBITDA (TTM)
-76.407
Management effectiveness
Valuation
Price to book
1.99
Price to tangible book (TTM)
1.99
Price to free cash flow (TTM)
-2.754
Free cash flow yield (TTM)
-36.32%
Free cash flow per share (TTM)
-575.25%
Growth
Bulls say / Bears say
Sionna Therapeutics successfully closed its upsized initial public offering, raising approximately $219.2 million, which strengthens its financial position for future development. (nasdaq.com)
Analysts from TD Cowen, Stifel Nicolaus, and Guggenheim have initiated coverage on Sionna Therapeutics with 'buy' ratings, indicating strong confidence in the company's potential. (defenseworld.net)
The company's focus on developing novel medicines to normalize CFTR protein function positions it to potentially revolutionize cystic fibrosis treatment, addressing a significant unmet medical need. (nasdaq.com)
Sionna Therapeutics reported a quarterly loss of $3.38 per share, missing analysts' consensus estimates by $0.70, leading to a new 52-week low in stock price. (marketbeat.com)
As a clinical-stage biopharmaceutical company, Sionna faces inherent risks associated with drug development, including potential delays or failures in clinical trials, which could negatively impact stock performance. (nasdaq.com)
The company's reliance on future funding from its initial public offering indicates dependence on market conditions and successful execution of its development plans, which carries financial uncertainty. (nasdaq.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jun 2025.
SION News
AllArticlesVideos
Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model
GlobeNewsWire·3 weeks ago
Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference
GlobeNewsWire·1 month ago
Sionna Therapeutics Reports First Quarter 2025 Financial Results
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Sionna Therapeutics, Inc. stock?
Sionna Therapeutics, Inc. (SION) has a market cap of $698M as of June 30, 2025.
What is the P/E ratio for Sionna Therapeutics, Inc. stock?
The price to earnings (P/E) ratio for Sionna Therapeutics, Inc. (SION) stock is 0 as of June 30, 2025.
Does Sionna Therapeutics, Inc. stock pay dividends?
No, Sionna Therapeutics, Inc. (SION) stock does not pay dividends to its shareholders as of June 30, 2025.
When is the next Sionna Therapeutics, Inc. dividend payment date?
Sionna Therapeutics, Inc. (SION) stock does not pay dividends to its shareholders.
What is the beta indicator for Sionna Therapeutics, Inc.?
Sionna Therapeutics, Inc. (SION) does not currently have a Beta indicator.